Trial Search Results
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.
Stanford is currently accepting patients for this trial.
Collaborator: Banner Alzheimer's Institute
- Biological: CAD106 Immunotherapy
- Other: Placebo to CAD106
- Drug: CNP520
- Other: Placebo to CNP520
- Other: Alum
Phase 2/Phase 3
Key Inclusion Criteria:
- Consented to receive disclosure of their risk estimates to develop clinical symptoms
of AD based on their APOE genotype.
- Male or female, age 60 to 75 years inclusive. Females were to be post-menopausal.
- Mini-Mental State Examination (MMSE) total score ≥ 24 and cognitively unimpaired as
evaluated by memory tests
- Homozygous APOE4 genotype.
- Participant willing to have a study partner.
Key Exclusion Criteria:
- Any disability that prevented the participant from completing all study requirements.
- Current medical or neurological condition that could have impacted cognition or
performance on cognitive assessments.
- Advanced, severe progressive or unstable disease that may have interfered with the
safety, tolerability and study assessments, or put the participant at special risk.
- History of malignancy of any organ system, treated or untreated, within 60 months
prior to screening.
- History of hypersensitivity to any of the investigational drugs or their excipients /
adjuvant or to drugs of similar chemical classes.
- Indication or on current treatment with ChEIs and/or another AD treatment (e.g.
- Contraindication or intolerance to MRI or PET investigations (with fluorinated radio
- Brain MRI results showing findings unrelated to AD that, in the opinion of the
Investigator could have been a leading cause to future cognitive decline, pose a risk
to the participant, or prevent a satisfactory MRI assessment for safety monitoring.
- Suicidal Ideation in the past six months or Suicidal Behavior in the past two years,
prior to screening.
- A positive drug screen at Screening, if, in the Investigator's opinion, this was due
to drug abuse.
- Significantly abnormal laboratory results at Screening, or infection not as a result
of a temporary condition.
- Current clinically significant ECG findings. For Cohort - I only: Participants with
previous organ transplantation or stem cell transplantation, or indication for
treatment with anti-coagulants.
For Cohort - II only: Participants with depigmenting or hypopigmenting conditions (e.g.
albinism vitiligo) or active / history of chronic urticarial in the past year.
Ages Eligible for Study
60 Years - 75 Years
Genders Eligible for Study